Anti-UGT1A9 Antibody

This polyclonal antibody from Antibodies.com targets UGT1A9 (UDP-glucuronosyltransferase 1A9), a key Phase II drug-metabolizing enzyme predominantly expressed in liver and intestinal tissues. UGT1A9 catalyzes the transfer of glucuronic acid from UDP-glucuronic acid to substrates including clinically important drugs, dietary polyphenols, and endogenous compounds such as steroid hormones and bilirubin, making it central to studies of xenobiotic clearance, hepatic function, and interindividual variability in drug response.

Raised in rabbit and supplied as 100 µl of unconjugated polyclonal antiserum, the reagent is validated for Western blot, immunohistochemistry, and immunofluorescence applications across human, mouse, and rat samples. The unconjugated format allows researchers to pair the antibody with their preferred secondary detection systems, whether HRP, fluorophore, or biotin, depending on the experimental workflow.

Because the antibody is polyclonal, it recognizes multiple epitopes on the UGT1A9 protein, an advantage in applications where target expression is low or where partial denaturation has occurred. For Western blot, lysates prepared from hepatic tissue or UGT1A9-transfected cell lines are commonly used as positive controls; for IHC, formalin-fixed paraffin-embedded liver sections show characteristic cytoplasmic staining in hepatocytes. Standard handling practice includes aliquoting upon receipt to avoid repeated freeze-thaw cycles, which helps preserve antibody activity over long-term storage. For research use only.